MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of “Hold” from Analysts

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have been assigned a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $35.00.

A number of brokerages recently issued reports on INKT. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded MiNK Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Zacks Research upgraded shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th.

MiNK Therapeutics Price Performance

NASDAQ INKT opened at $11.90 on Friday. The firm’s fifty day moving average price is $12.55 and its 200 day moving average price is $13.67. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00. The company has a market capitalization of $55.81 million, a price-to-earnings ratio of -3.93 and a beta of 0.35.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21. As a group, sell-side analysts forecast that MiNK Therapeutics will post -2.75 earnings per share for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.